



**A Comparative Study of the Anti-inflammatory and  
Immunomodulatory Effect of the Anti-Angiogenic Ranibizumab  
and IL-6R Antagonist Tocilizumab in Rheumatoid Arthritis Model**

*Thesis  
Presented by*

***Amany El-Shahawy Abdel-Maged***

*B. Pharm. Sc. Ain Shams University (2012)*

*Q.C Specialist at National Organization for Research and Control of Biologicals  
(NORCB) (2013)*

**Submitted for the Partial Fulfillment of Master's Degree  
In Pharmaceutical Sciences  
(Pharmacology and Toxicology)**

*Supervised By:*

**Dr. Mohammad Mabrouk Aboulwafa**

Professor and Head of Department of Microbiology and Immunology  
Faculty of Pharmacy, Ain Shams University

**Dr. Samar Saad Eldeen Azab**

Assistant Professor of Pharmacology and Toxicology  
Faculty of Pharmacy, Ain Shams University

**Dr. Amal Kamal Said**

Lecturer of Pharmacology and Toxicology  
Faculty of Pharmacy, Ain Shams University

**Faculty of Pharmacy- Ain Shams University  
2017**

**Dedication**

Every challenging work requires self-efforts as well as guidance of elders especially those who were very close to our hearts. I dedicated my humble effort to my sweet & loving **Mother, Brother & Sister** for their emotional & financial support. I confess that without them I couldn't do anything in my life & Because of their unconditional love and prayers, I had the chance to complete this thesis.

I have learned from my **prof. Dr. Omar Ghonim**, Assistant Professor of Analytical chemistry, Faculty of Pharmacy, Ain Shams University "Always do the best job because your reputation is worth more than a quick profit" So, I dedicated all my work, thesis and research to him. He always supported me & encouraged me to go on every adventure. It was my honor to have a Prof Like him in my life.

This work is also dedicated to my dearest friend **Dr. Mohammad Ghali** for his endless support, keeping my spirit up with all the constant encouragement to accomplish the thesis work. I am truly thankful for having you in my life.

Finally, I must express my very profound gratitude to my best friends **Samar Mohsen, Asmaa Yousef, Alsaeed Ahmed, Ahmed El-sayed, Eman A. Wally, Hoda El-Saed, Randa Hamed, Zahraa, Amina & all my friends in biotechnology lab** under supervision of **Dr. Mai Allam** for providing me with unfailing support and continuous encouragement during my years of study and during the researching process & thesis writing. This thesis wouldn't have been possible without them. Thanks so much.

## *Acknowledgements*

---

### **Acknowledgements**

Firstly & before anything, I am thankful to Allah for his guidance and blessing. Literally, I am sure that this work would have never been achieved without his help.

## *Acknowledgements*

---

Actually, I would like to express my sincere gratitude to my supervisor **Dr. Samar SaadEldeen Azab**, Assistant Professor of Pharmacology & Toxicology, Faculty of Pharmacy, Ain Shams University, for the continuous support of my master study & related research, for her patience, motivation & immense knowledge. Her guidance helped me in all time of research & writing of this thesis. I couldn't have imagined having a better advisor & mentor for my master study. A very special thanks is paid to her for choosing the point of this thesis and for providing me with a good environment and facilities to complete all the practical work throughout the whole study. I would like to thank her for her experience in the process of researching, also for the time she spared during revising this thesis.

I also wish to express my deep thanks and appreciations to my supervisor **Dr. Mohammad Mabrouk Aboulwafa**, Professor of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University, for his kind supervision and guidance throughout this work. He is actually a great example of outstanding university professor at both the ethical and scientific levels. I thank him for accepting me as a candidate under his supervision, endless co-operation, fruitful and indispensable advice & valuable guidance as well as his interest and concern about my progress. Also, a very special thanks is paid to him for the time he spared during revising this thesis.

## *Acknowledgements*

---

Also, I am greatly thankful to my supervisor **Dr. Amal Kamal Sayed**, lecturer in Pharmacology & Toxicology, Faculty of Pharmacy, Ain Shams University, for her kind supervision, endless support, as well as valuable instructions and guidance throughout this work. I would like to thank her for her experience in the process of researching, also for the time she spared during revising this thesis.

My sincere thanks and appreciations also goes to **Dr. Amany Gad**, Lecturer in Pharmacology & Toxicology, NODCAR, who provided me an opportunity to join their team as intern & who gave access to the laboratory & researches facilities. Without her precious support it wouldn't be possible to conduct this research. I thank her for her insightful comments & encouragement, but also for the hard question which incented me to widen my research from various prespectives.

I owe all the sincerest appreciation and gratitude to **Dr. Nahla Shehata**, Chairman of National organization of research & control of biologicals (NORCB) whose sincerity and encouragement I will never forget. All credit goes to her for generous help, continuous encouragement, enthusiastic support & her kindness.

## *Acknowledgements*

---

Great thanks & appreciations goes to **Dr. Mohamed El-Shazly**, Associate Professor in Pharmacognosy Department, Faculty of Pharmacy, Ain Shams University, for his support and wealth of knowledge, he has encouraged me throughout the process of researching and writing. I would like to thank him for the time he spared with me during solving any obstacle in my master study. He has taught me more than I could ever give him credit. He has encouraged and challenged me throughout the process of searching and writing this thesis and never accepting anything other than my best.

*Amany El-Shahawy*



Rheumatoid arthritis (RA) is a chronic and progressive autoimmune inflammatory disease associated with irreversible joint destruction that leads to permanent motor disability and compromised quality of life. Although the precise etiology of RA remains obscure, heightened immune response is thought to play a vital role in provoking joint inflammation and bone erosion. This Study aims at evaluating the anti-inflammatory and immuno-modulatory effects of two monoclonal antibodies Ranibizumab (RANI) as anti-VEGF managing agent and Tocilizumab (TCZ) as interleukin-6 receptor (IL-6R) antagonist, against adjuvant induced arthritis in rats. CFA-induced arthritic rats were treated for three consecutive weeks with MTX, TCZ, RANI monotherapy and MTX-TCZ co-therapy. Arthritic score, gait score, ankle diameter, paw thickness, bone erosion markers, inflammatory and angiogenic cytokines and apoptotic markers were determined to assess the anti-arthritic effect. Liver enzymes and histopathological examination of liver and spleen were assessed to evaluate the toxicity profile of the tested therapeutic agents. MTX, TCZ, RANI monotherapy and MTX-TCZ co-therapy significantly enhanced the anti-arthritic parameters in comparison with the CFA-induced arthritic rats. Ranibizumab (RANI) (anti-VEGF managing agent) showed more potent effect than the standard anti-rheumatic drugs Methotrexate (MTX) or Tocilizumab (TCZ). In addition, the combined therapy (MTX-TCZ) proved better efficacy than single agents MTX and TCZ.

---

**Keywords:** Adjuvant Induced Arthritis – Rats – Ranibizumab – Tocilizumab – Immune Response.

---

**List of contents**

<b>Subject</b>	<b>Page</b>
<b>List of abbreviations</b>	<b>I</b>
<b>List of tables</b>	<b>V</b>
<b>List of figures</b>	<b>VII</b>
<b>Introduction</b>	
<b>1.Rheumaroid Arthritis (RA)</b>	
1.1. Definition of RA	<b>1</b>
1.2. Prevalence of RA	<b>1</b>
1.3. Etiology of RA	<b>2</b>
1.4. Signs and Symptoms of RA	<b>2</b>
1.5. Pathogenesis of RA	<b>3</b>
1.6. Risks of RA	<b>15</b>
1.7. Diagnosis of RA	<b>15</b>
1.8. Prognosis of RA	<b>17</b>
1.9. Management of RA	<b>19</b>
<b>2. Complete Freund's adjuvants (CFA)</b>	<b>25</b>
<b>3.Methotrexate</b>	
3.1. Clinical Indications	<b>28</b>
3.2. Pharmacodynamics	<b>29</b>
3.3. Pharmacokinetics	<b>30</b>
3.4. Adverse effects	<b>31</b>
<b>4.Tocilizumab</b>	
4.1. Clinical Indications	<b>32</b>
4.2. Pharmacodynamics	<b>32</b>
4.3. Pharmacokinetics	<b>34</b>



<b>Subject</b>	<b>Page</b>
4.4. Adverse effects	<b>35</b>
<b>5. Ranibizumab</b>	
5.1. Clinical Indications	<b>36</b>
5.2. Pharmacodynamics	<b>37</b>
5.3. Pharmacokinetics	<b>37</b>
5.4. Adverse effects	<b>38</b>
<b>Aim of the work</b>	<b>39</b>
<b>Materials and methods</b>	
1. Experimental model of Rheumatoid Arthritis	<b>41</b>
2. <i>Materials</i>	
2.1. Animals	<b>45</b>
2.2. Drugs	<b>46</b>
2.3. Chemicals	<b>47</b>
2.4. Solutions	<b>48</b>
2.5. Buffers	<b>50</b>
2.6. Equipments	<b>52</b>
2.7. Ready-made Kits	<b>53</b>
3. <i>Methods</i>	
<b>3.1. Assessment of arthritis severity</b>	
3.1.1. Observational scoring of arthritic index	<b>57</b>
3.1.2. Observational scoring of gait	<b>58</b>
3.1.3. Ankle diameter by Vernier caliper	<b>59</b>
3.1.4. Paw thickness by Vernier caliper	<b>60</b>
3.1.5. Histopathological examination of hind paw	<b>61</b>
<b>3.2. Examination of inflammatory markers</b>	
3.2.1. Immunohistochemical examination of paw	<b>62</b>

<b>Subject</b>	<b>Page</b>
3.2.2. IL-6	<b>63</b>
<b>3.3. Examination of angiogenic markers</b>	
3.3.1. TGF beta	<b>67</b>
3.3.2. VEGF	<b>72</b>
<b>3.4. Evaluation of apoptotic markers</b>	<b>76</b>
3.4.1. Bax	
3.4.2. BCl-2	
3.4.3. Caspase-3	
<b>3.5. Assessment of bone erosion markers</b>	<b>84</b>
3.5.1. OPG	
3.5.2. RANKL	
<b>3.6. Toxicity Profile</b>	
3.6.1. Liver enzymes (ALT & AST)	<b>90</b>
3.6.2. Histopathological examination of liver and spleen	<b>93</b>
<b>Statistical Analysis</b>	<b>93</b>
<b>Results</b>	<b>94</b>
<b>Discussion</b>	<b>128</b>
<b>Summary and conclusion</b>	<b>137</b>
<b>References</b>	<b>142</b>
<b>Arabic summary</b>	<b>٢ -١</b>

**List of Abbreviations**

<b>ABC</b>	ATP-binding cassette
<b>ACPAs</b>	Anti-citrullinated protein antibodies
<b>Ag</b>	Antigen
<b>ALT</b>	Alanine aminotransferase
<b>AMD</b>	Age-related macular degeneration
<b>ANOVA</b>	Analysis of variance
<b>AST</b>	Aspartate aminotransferase
<b>B-Cell</b>	B lymphocyte
<b>BCl-2</b>	B-cell lymphoma 2
<b>CALA</b>	Collagen antibody- induced arthritis
<b>CD28</b>	Cluster of differentiation 28
<b>CD40</b>	Cluster of differentiation 40
<b>CD40L</b>	Cluster of differentiation 40 Ligand
<b>CD80</b>	Cluster of differentiation 80
<b>CFA</b>	Complete Freund's adjuvants
<b>CIA</b>	Collagen-induced arthritis
<b>COX-II</b>	Cyclooxygenase-II
<b>CRP</b>	C-reactive protein
<b>DC</b>	Dendritic cell
<b>DHFR</b>	Dihydrofolate reductase
<b>DISC</b>	Death- inducing signaling complex
<b>DMARDs</b>	Disease modifying anti-rheumatic Drugs
<b>dTMP</b>	Deoxythymidine monophosphate
<b>dUMP</b>	Deoxyuridine monophosphate
<b>ELISA</b>	Enzyme linked immunosorbent assay

<b>EMEA</b>	The European Medicines Agency's
<b>Fab</b>	Fragment antigen binding
<b>FADD</b>	Fas associated death domain
<b>Fas</b>	First apoptosis signal
<b>FasL</b>	First apoptosis signal ligand
<b>FPGH</b>	Folylpoly glutamate hydrolase
<b>FPGS</b>	Folylpoly glutamyl synthetase
<b>FR</b>	Folate receptor
<b>GAPDH</b>	Glyceraldehyde 3-phosphate dehydrogenase
<b>gp-130</b>	Signal transducer glycoprotein 130
<b>H&amp;E</b>	Hematoxylin and eosin
<b>IFA</b>	Incomplete Freund's adjuvant
<b>IFN<math>\gamma</math></b>	Interferon gamma
<b>IL-6R</b>	Interleukin-6 receptor
<b>ILs</b>	Interleukins
<b>IL-2</b>	Interleukin-2
<b>IL-17</b>	Interleukin-17
<b>IL-18</b>	Interleukin-18
<b>IL-15</b>	Interleukin-15
<b>IL-1</b>	Interleukin-1
<b>IL-6</b>	Interleukin-6
<b>INN</b>	International Non-Proprietary Name
<b>IP</b>	Intraperitoneal
<b>ITV</b>	Intravitreal
<b>JACK/ STAT</b>	Janus-activated kinase-signal transducer and activator of transcription
<b>JAK</b>	Janus kinase

<b>M-CSF</b>	Macrophage colony-stimulating factor
<b>MHC-II</b>	Major histocompatibility Complex class II molecules
<b>mIL-6R</b>	Membrane bound Il-6 receptor
<b>MMPs</b>	Matrix metalloproteinases
<b>MTX</b>	Methotrexate
<b>MTX-PG</b>	PolyGlutamation of methotrexate
<b>NF-<math>\kappa</math>B</b>	Nuclear factor kappa-B
<b>NSAID</b>	Non-Steroidal anti-inflammatory drugs
<b>OD</b>	Optical density
<b>OPG</b>	Osteoprotegerin
<b>P</b>	Phosphate group (phosphorylation)
<b>P53</b>	Protein 53
<b>PBS</b>	Phosphate buffer saline
<b>PCD</b>	Programmed cell death
<b>PMSF</b>	Phenylmethanesulfonyl fluoride
<b>qPCR</b>	Quantitative polymerase chain reaction
<b>RA</b>	Rheumatoid Arthritis
<b>RANKL</b>	Receptor activator of nuclear factor kappa-B ligand
<b>RANK</b>	Receptor activator of nuclear factor kappa-B
<b>RANI</b>	Ranibizumab
<b>RFC</b>	Reduced folate carrier
<b>RF</b>	Rheumatoid Factor
<b>RT-PCR</b>	Reverse transcription-polymerase chain reaction

<b>SD</b>	Standard deviation
<b>SDS-PAGE</b>	Sodium dodecyl sulfate- polyacrylamide gel electrophoresis
<b>SEM</b>	Standard error of mean
<b>sIL-6R</b>	Soluble IL-6 receptor
<b>SOCS3</b>	Suppressor of cytokine signaling 3
<b>STAT3</b>	Signal transducer and activator of transcription 3
<b>T-cell</b>	T lymphocyte
<b>TCZ</b>	Tocilizumab
<b>Th1</b>	Lymphocyte T-helper 1 cell
<b>Th17</b>	Lymphocyte T-helper 17 cell
<b>TGF<math>\beta</math></b>	Transforming growth factor beta
<b>TLR</b>	Toll Like Receptor
<b>TMYS</b>	Thymidylate synthetase
<b>TNF-<math>\alpha</math></b>	Tumor necrotic factor- alpha
<b>TRADD</b>	Tumor necrosis factor receptor associated death domain
<b>Treg</b>	Regulatory T cell
<b>VEGF</b>	Vascular endothelial growth factor
<b>WHO</b>	World Health Organization

---

**List of Tables**

<b>Table NO.</b>	<b>Table Title</b>	<b>Page No.</b>
<b>1</b>	Stages of Rheumatoid arthritis progression	<b>17</b>
<b>2</b>	Difference between pharmaceuticals and biological products	<b>23</b>
<b>3</b>	Arthritic scoring system	<b>57</b>
<b>4</b>	Gait scoring system	<b>58</b>
<b>5</b>	Primer sequences used for RT-qPCR	<b>87</b>
<b>6</b>	Effect of Methotrexate (MTX), Tocilizumab (TCZ), Ranibizumab (RANI) and MTX+TCZ co-therapy on arthritic index score in adjuvant arthritic rats	<b>95</b>
<b>7</b>	Effect of Methotrexate (MTX), Tocilizumab (TCZ), Ranibizumab (RANI) and MTX+TCZ co-therapy on gait score in adjuvant arthritic rats	<b>97</b>
<b>8</b>	Effect of Methotrexate (MTX), Tocilizumab (TCZ), Ranibizumab (RANI) and MTX+TCZ co-therapy on ankle diameter in adjuvant arthritic rats	<b>99</b>
<b>9</b>	Effect of Methotrexate (MTX), Tocilizumab (TCZ), Ranibizumab (RANI) and MTX+TCZ co-therapy on paw thickness in adjuvant arthritic rats	<b>102</b>
<b>10</b>	Assessment of histopathological alterations in left hind paw tissues for normal and CFA induced arthritic rats with or without Methotrexate (MTX), Tocilizumab (TCZ), Ranibizumab (RANI), and MTX-TCZ	<b>107</b>